Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 73

1.

A phase I study of bexarotene and rosiglitazone in patients with refractory cancers.

Read WL, Baggstrom MQ, Fracasso PM, Govindan R.

Chemotherapy. 2008;54(3):236-41. doi: 10.1159/000140468. Epub 2008 Jun 18.

PMID:
18560232
2.

Phase 2 and 3 clinical trial of oral bexarotene (Targretin capsules) for the treatment of refractory or persistent early-stage cutaneous T-cell lymphoma.

Duvic M, Martin AG, Kim Y, Olsen E, Wood GS, Crowley CA, Yocum RC; Worldwide Bexarotene Study Group.

Arch Dermatol. 2001 May;137(5):581-93.

PMID:
11346336
3.

Optimizing bexarotene therapy for cutaneous T-cell lymphoma.

Talpur R, Ward S, Apisarnthanarax N, Breuer-Mcham J, Duvic M.

J Am Acad Dermatol. 2002 Nov;47(5):672-84.

PMID:
12399758
4.

A phase I study of bexarotene, a retinoic X receptor agonist, in non-M3 acute myeloid leukemia.

Tsai DE, Luger SM, Andreadis C, Vogl DT, Kemner A, Potuzak M, Goradia A, Loren AW, Perl AE, Schuster SJ, Porter DL, Stadtmauer EA, Goldstein SC, Thompson JE, Swider C, Bagg A, Mato AR, Carroll M.

Clin Cancer Res. 2008 Sep 1;14(17):5619-25. doi: 10.1158/1078-0432.CCR-07-5185.

5.

Safety and efficacy of low-dose bexarotene and PUVA in the treatment of patients with mycosis fungoides.

Papadavid E, Antoniou C, Nikolaou V, Siakantaris M, Vassilakopoulos TP, Stratigos A, Stavrianeas N, Katsambas A.

Am J Clin Dermatol. 2008;9(3):169-73.

PMID:
18429646
6.

Evaluation of the efficacy of the combination of oral bexarotene and methotrexate for the treatment of early stage treatment-refractory cutaneous T-cell lymphoma.

Kannangara AP, Levitan D, Fleischer AB Jr.

J Dermatolog Treat. 2009;20(3):169-76. doi: 10.1080/09546630802562427.

PMID:
19016373
7.

Retinoid and thiazolidinedione therapies in melanoma: an analysis of differential response based on nuclear hormone receptor expression.

Klopper JP, Sharma V, Berenz A, Hays WR, Loi M, Pugazhenthi U, Said S, Haugen BR.

Mol Cancer. 2009 Mar 6;8:16. doi: 10.1186/1476-4598-8-16.

8.

A phase I study of docetaxel and bexarotene.

Wildi JD, Baggstrom MQ, Suresh R, Read W, Fracasso PM, Govindan R.

Chemotherapy. 2008;54(2):125-30. doi: 10.1159/000119706. Epub 2008 Mar 7.

PMID:
18332628
9.

Systemic treatment of psoriatic patients with bexarotene decreases epidermal proliferation and parameters for inflammation, and improves differentiation in lesional skin.

Smit JV, de Jong EM, van Hooijdonk CA, Otero ME, Boezeman JB, van de Kerkhof PC.

J Am Acad Dermatol. 2004 Aug;51(2):257-64.

PMID:
15280845
10.

Bexarotene therapy for mycosis fungoides and Sézary syndrome.

Abbott RA, Whittaker SJ, Morris SL, Russell-Jones R, Hung T, Bashir SJ, Scarisbrick JJ.

Br J Dermatol. 2009 Jun;160(6):1299-307. doi: 10.1111/j.1365-2133.2009.09037.x. Epub 2009 Feb 16.

PMID:
19222457
11.

[Bexarotene therapy in folliculotropic cutaneous T-cell lymphoma].

Drugeon C, Charlat I, Boulinguez S, Viraben R.

Ann Dermatol Venereol. 2007 Aug-Sep;134(8-9):639-43. French.

PMID:
17925686
12.

Bexarotene.

Lowe MN, Plosker GL.

Am J Clin Dermatol. 2000 Jul-Aug;1(4):245-50; discussion 251-2. Review.

PMID:
11702369
13.
14.

Vorinostat combined with bexarotene for treatment of cutaneous T-cell lymphoma: in vitro and phase I clinical evidence supporting augmentation of retinoic acid receptor/retinoid X receptor activation by histone deacetylase inhibition.

Dummer R, Beyer M, Hymes K, Epping MT, Bernards R, Steinhoff M, Sterry W, Kerl H, Heath K, Ahern JD, Hardwick JS, Garcia-Vargas J, Baumann K, Rizvi S, Frankel SR, Whittaker SJ, Assaf C.

Leuk Lymphoma. 2012 Aug;53(8):1501-8. doi: 10.3109/10428194.2012.656625. Epub 2012 Feb 13.

PMID:
22239668
15.

Bexarotene: a clinical review.

Farol LT, Hymes KB.

Expert Rev Anticancer Ther. 2004 Apr;4(2):180-8. Review.

PMID:
15056048
16.

Comparison of selective retinoic acid receptor- and retinoic X receptor-mediated efficacy, tolerance, and survival in cutaneous t-cell lymphoma.

Querfeld C, Rosen ST, Guitart J, Rademaker A, Fung BB, Posten W, Kuzel TM.

J Am Acad Dermatol. 2004 Jul;51(1):25-32.

PMID:
15243520
17.

Use of peroxisome proliferator-activated receptor gamma agonists as adjunctive treatment for Plasmodium falciparum malaria: a randomized, double-blind, placebo-controlled trial.

Boggild AK, Krudsood S, Patel SN, Serghides L, Tangpukdee N, Katz K, Wilairatana P, Liles WC, Looareesuwan S, Kain KC.

Clin Infect Dis. 2009 Sep 15;49(6):841-9. doi: 10.1086/605431.

PMID:
19673614
18.

[Treatment of cutaneous T-cell lymphomas with bexarotene].

Lasa O, Izu R, Acebo E, Eguino P, Díaz-Pérez JL.

Actas Dermosifiliogr. 2005 Dec;96(10):669-73. Spanish. Erratum in: Actas Dermosifiliogr. 2006 Mar;97(2):102.

PMID:
16476317
19.

A phase II multicenter clinical trial of systemic bexarotene in psoriasis.

Smit JV, Franssen ME, de Jong EM, Lambert J, Roseeuw DI, De Weert J, Yocum RC, Stevens VJ, van De Kerkhof PC.

J Am Acad Dermatol. 2004 Aug;51(2):249-56.

PMID:
15280844
20.

Hypertriglyceridaemia with bexarotene in cutaneous T cell lymphoma: the role of omega-3 fatty acids.

Musolino A, Panebianco M, Zendri E, Santini M, Di Nuzzo S, Ardizzoni A.

Br J Haematol. 2009 Apr;145(1):84-6. doi: 10.1111/j.1365-2141.2009.07596.x. Epub 2009 Feb 4.

PMID:
19208096

Supplemental Content

Support Center